Cambridge Cognition Expands Partnership with Actinogen Medical
Cambridge Cognition Holdings plc has announced an expansion of its partnership with Actinogen Medical Limited, reinforcing its support for the phase 2b/3 XanaMIA trial – a cutting-edge study targeting Alzheimer’s disease.
Building on the success of the initial phase of the study, Cambridge Cognition’s state-of-the-art digital tools will continue to play a pivotal role in enabling precise clinical measurements for this vital research.
Dementia currently affects 47 million people globally, with Alzheimer’s disease being one of the most significant contributors to this growing health crisis. Actinogen Medical is at the forefront of developing innovative therapies, focusing on managing elevated brain cortisol levels to slow or even halt the progression of this debilitating disease.
The XanaMIA trial is a critical step forward, involving 220 patients with mild to moderate dementia due to Alzheimer’s and elevated levels of the plasma biomarker pTau181.
Over a 36-week period, participants will receive either a 10 mg dose of emestedastat (Xanamem) or a placebo, with the trial’s primary endpoint measured through the Clinical Dementia Rating scale – Sum of Boxes (CDR-SB).
Cambridge Cognition is proud to lend its expertise to this initiative. The company’s validated digital tools, including the CANTAB Attention and working memory battery, and the automated quality assurance solution, AQUA, are set to provide unmatched precision and reliability in secondary cognitive assessments.
These tools ensure exceptional data quality and comparability, critical for Actinogen’s clinical development programme.
Commenting on the collaboration, Cambridge Cognition’s Joint Managing Director and Chief Operating Officer expressed pride in deepening ties with Actinogen for this landmark research. They noted that their integrated platform optimises clinical assessments while upholding exceptional data quality standards.
Actinogen’s CEO and Managing Director shared similar sentiments, emphasising the importance of robust and reliable data in advancing Alzheimer’s research.
They stated that Cambridge Cognition’s comprehensive solution strengthens confidence in data integrity for the XanaMIA trial, helping them deliver on their commitment to innovate in Alzheimer’s treatment.
This partnership further solidifies the proven effectiveness of Cambridge Cognition’s solutions in advancing critical Alzheimer’s research. By providing tools that ensure greater comparability and superior data quality, the collaboration underscores a shared commitment to addressing the challenges of Alzheimer’s disease with cutting-edge innovation.
In conclusion, the strengthened partnership between Cambridge Cognition and Actinogen Medical marks a significant milestone in Alzheimer’s research.
As Actinogen continues to develop its groundbreaking therapy, supported by Cambridge Cognition’s advanced tools and expertise, this collaboration holds the promise of meaningful progress in the fight against dementia – offering hope to millions worldwide.
News Credits: Actinogen boosts trial with Cambridge Cognition’s digital suite
Things you may also like:
- New Hope for Prostate Cancer Patients Resistant to Hormone Therapy
- Innovative Food Ingredients Launches New Divisions
- NICE Approves Lynparza for Advanced Breast Cancer Treatment